Inside the ICE House
Pfizer CFO Dave Denton on Oncology, Obesity, and Pfizer’s Next Growth Cycle
32m
Pfizer CFO Dave Denton goes Inside the ICE House to discuss how the company is navigating its post‑COVID transition and positioning itself for a return to sustainable growth later this decade. He details Pfizer’s major strategic investments in oncology and metabolic health, including the Seagen and Metsera deals, and explains how proven platforms, global scale, and financial discipline are central to those moves. Denton also shares how execution, patient‑centric innovation, and emerging technologies like AI are shaping the next chapter of Pfizer’s growth story.
Up Next in 2026 | Inside the ICE House
-
Global X ETFs Pedro Palandrani on the...
Global X ETFs’ Pedro Palandrani goes Inside the ICE House to discuss the launch of the Global X NYSE 100 ETF and how it redefines innovation investing. He explains how the fund expands beyond traditional tech classifications to capture tech-enabled leaders across multiple sectors and exchanges us...
-
April Markets in Focus: Headline Driv...
Phil Rosen goes Inside The ICE House to explain how Middle East tensions are driving short-term volatility and testing investor confidence. He outlines why history suggests geopolitical shocks and oil price swings are typically temporary, often rewarding investors who stay the course. Rosen argue...
-
Vinson & Elkins Chair Keith Fullenwei...
Vinson & Elkins Chair Keith Fullenweider joins Inside the ICE House to break down the forces reshaping business, finance, and the legal industry. He discusses the rise of new financial hubs, the growing impact of AI on infrastructure and dealmaking, and why power and data centers are now critical...
